Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ranferon-12
- Development stage
- Unknown
- Lead developer
- Sun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ranferon-12 is an oral hematinic fixed-dose combination product containing iron (as ferric ammonium citrate or ferrous fumarate), folic acid (vitamin B9), and cyanocobalamin (vitamin B12). Some formulations, particularly the capsules, also include ascorbic acid (vitamin C) and zinc sulfate to enhance absorption and support cellular metabolism. It is primarily indicated for the prevention and treatment of iron deficiency anemia, nutritional anemias, and megaloblastic anemia, especially during periods of high physiological demand such as pregnancy, infancy, and childhood. The iron component replenishes depleted systemic iron stores and supports hemoglobin synthesis, while folic acid and vitamin B12 serve as essential cofactors for DNA synthesis and red blood cell maturation. Originally developed by Ranbaxy Laboratories (now part of Sun Pharma), Ranferon-12 is widely marketed as a syrup, elixir, or capsule to support healthy erythropoiesis and overall blood health.
- Brand names
- RanferonRanferon-12Ranferon12Ranferon 12
- Other names
- ferric ammonium citrate + folic acid + cyanocobalaminferrous fumarate + folic acid + cyanocobalaminiron + folic acid + vitamin B12
02
Targets
DHFR (Dihydrofolate reductase)Hb (Hemoglobin)MTR (Methionine synthase)MMUT (Methylmalonyl-coenzyme A mutase)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on Ranferon-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ranferon-12.